IMUNON to Hold Second Quarter 2023 Financial Results and Business Update Conference Call on Thursday, August 10, 2023
2023年8月3日 - 9:30PM
IMUNON, Inc. (NASDAQ:
IMNN), a clinical-stage drug-development company focused
on developing DNA-mediated immunotherapy and next-generation
vaccines, announces that the Company will host a conference call at
11:00 a.m. ET on Thursday, August 10, 2023 to discuss financial
results for the second quarter and six-months ended June 30, 2023
and provide an update on its clinical development of IMNN-001
(formerly GEN-1), a DNA-based interleukin-12 (IL-12) immunotherapy
in Phase 2 clinical development for the treatment of advanced-stage
ovarian cancer, and on its PlaCCine modality, a proprietary mono-
or multi-cistronic non-viral and synthetic DNA technology for the
expression of pathogen antigens, being evaluated in preclinical
studies for the development of next-generation vaccines.
To participate in the call, interested parties
may dial 866-777-2509 (Toll-Free/North America) or 412-317-5413
(International/Toll) and ask for the IMUNON Second Quarter 2023
Financial Results Call. The call will also be broadcast live at
www.imunon.com. It will be archived for replay until August 24,
2023 and can be accessed at 877-344-7529 (U.S. Toll Free),
855-669-9658 (Canada Toll Free) or 412-317-0088 (International
Toll) using replay access code 1202020. An audio replay of the call
will also be available at www.imunon.com for 90 days.
About IMUNON
IMUNON is a fully integrated, clinical stage
biotechnology company focused on advancing a portfolio of
innovative treatments that harness the body’s natural mechanisms to
generate safe, effective, and durable responses across a broad
array of human diseases, constituting a differentiating approach
from conventional therapies. Imunon is developing its non-viral DNA
technology across 4 modalities. The first modality, Theraplas®, is
developed for the coding of proteins and cytokines in the treatment
of solid tumors where an immunological approach is deemed
promising. The second modality, PlaCCine® is developed for the
coding of viral antigens that can elicit a strong immunological
response. This technology may represent a promising platform for
the development of vaccines in infectious diseases. The third
modality, Fixplas®, concerns the application of our DNA technology
to produce universal cancer vaccines also called tumor associated
antigen cancer vaccines. Finally, the fourth modality, which is
still in the discovery phase, Indiplas®, will focus on the
development of personalized cancer vaccines, or neoepitope cancer
vaccines.
The Company’s lead clinical program, IMNN-001,
is a DNA-based immunotherapy for the localized treatment of
advanced ovarian cancer currently in Phase II development. IMNN-001
works by instructing the body to produce safe and durable levels of
powerful cancer fighting molecules, such as interleukin-12 and
interferon gamma, at the tumor site. Additionally, the Company is
conducting IND enabling pre-clinical studies for the development of
a COVID-19 booster vaccine: IMNN-101. The Company has also
initiated pre-clinical work to develop a Trp2 tumor associated
antigen cancer vaccine in melanoma: IMNN-201 We will continue to
leverage these modalities and to advance the technological frontier
of plasmid DNA to better serve patients with difficult-to-treat
conditions. For more information on IMUNON,
visit www.imunon.com.
Forward-Looking Statements
IMUNON wishes to inform readers that
forward-looking statements in this news release are made pursuant
to the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995. Readers are cautioned that such
forward-looking statements involve risks and uncertainties
including, without limitation, unforeseen changes in the course of
research and development activities and in clinical trials; the
uncertainties of and difficulties in analyzing interim clinical
data; the significant expense, time and risk of failure of
conducting clinical trials; the need for IMUNON to evaluate its
future development plans; possible acquisitions or licenses of
other technologies, assets or businesses; possible actions by
customers, suppliers, competitors or regulatory authorities; and
other risks detailed from time to time in IMUNON’s periodic reports
and prospectuses filed with the Securities and Exchange Commission.
IMUNON assumes no obligation to update or supplement
forward-looking statements that become untrue because of subsequent
events, new information or otherwise.
Contacts:
IMUNON |
LHA Investor Relations |
Jeffrey W. Church |
Kim Sutton Golodetz |
Executive Vice President, CFO |
212-838-3777 |
and Corporate Secretary |
Kgolodetz@lhai.com |
609-482-2455 |
|
jchurch@imunon.com |
|
# # #
Imunon (NASDAQ:IMNN)
過去 株価チャート
から 4 2024 まで 5 2024
Imunon (NASDAQ:IMNN)
過去 株価チャート
から 5 2023 まで 5 2024